Onesource Specialty Pharma Ltd (ONESOURCE) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- The new DDC Line 2 is now operational, handling 500L batches, which is 2.5 times larger than Line 1, significantly boosting output.
- Management reaffirmed its FY28 guidance of $400 million in revenue and $160 million in EBITDA, expecting a stronger second half.
- Product supplies to Dr. Reddy's will commence in Q3 FY27, starting with Canada, marking a crucial step in market relaunch.
Performance Overview
- Reported a strong Q2 with the third consecutive quarter of sequential growth, driven by expanded DDC capacity.
- Revenue grew 37% year-on-year and 15% sequentially, exceeding 5 billion Indian rupees for the quarter.
- EBITDA increased 53% year-on-year and 32% sequentially, demonstrating strong operating leverage.
- The second DDC cartridge line became operational in September, doubling total sterile production days.
- Biologics segment is emerging as a key growth pillar with multiple new project wins from new and existing customers.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.